Sunflower Pharmaceuticals Group Co Ltd (002737) - Total Liabilities
Based on the latest financial reports, Sunflower Pharmaceuticals Group Co Ltd (002737) has total liabilities worth CN¥891.55 Million CNY (≈ $130.46 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Sunflower Pharmaceuticals Group Co Ltd generate cash to assess how effectively this company generates cash.
Sunflower Pharmaceuticals Group Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Sunflower Pharmaceuticals Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 002737 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Sunflower Pharmaceuticals Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sunflower Pharmaceuticals Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
China | CN¥1.10 Billion |
|
Shenzhen Hui Chuang Da Technology Co.Ltd
SHE:300909
|
China | CN¥1.23 Billion |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
India | Rs1.63 Billion |
|
Shanghai Runda Med Tech Co
SHG:603108
|
China | CN¥8.41 Billion |
|
LianChuang Electronic Technology Co Ltd
SHE:002036
|
China | CN¥14.30 Billion |
|
Kingsgate Consolidated Ltd
AU:KCN
|
Australia | AU$222.47 Million |
|
Anhui Guofeng Plastic Industry Co Ltd
SHE:000859
|
China | CN¥1.84 Billion |
|
Jiangxi Guoguang Commercial Chains Co Ltd
SHG:605188
|
China | CN¥1.61 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Sunflower Pharmaceuticals Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002737 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sunflower Pharmaceuticals Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sunflower Pharmaceuticals Group Co Ltd (2011–2024)
The table below shows the annual total liabilities of Sunflower Pharmaceuticals Group Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.24 Billion ≈ $180.85 Million |
-34.16% |
| 2023-12-31 | CN¥1.88 Billion ≈ $274.70 Million |
-27.60% |
| 2022-12-31 | CN¥2.59 Billion ≈ $379.44 Million |
+52.52% |
| 2021-12-31 | CN¥1.70 Billion ≈ $248.78 Million |
-1.31% |
| 2020-12-31 | CN¥1.72 Billion ≈ $252.07 Million |
-8.36% |
| 2019-12-31 | CN¥1.88 Billion ≈ $275.05 Million |
+15.87% |
| 2018-12-31 | CN¥1.62 Billion ≈ $237.38 Million |
+23.97% |
| 2017-12-31 | CN¥1.31 Billion ≈ $191.49 Million |
-7.80% |
| 2016-12-31 | CN¥1.42 Billion ≈ $207.68 Million |
+22.97% |
| 2015-12-31 | CN¥1.15 Billion ≈ $168.89 Million |
-20.59% |
| 2014-12-31 | CN¥1.45 Billion ≈ $212.67 Million |
+18.20% |
| 2013-12-31 | CN¥1.23 Billion ≈ $179.92 Million |
+8.23% |
| 2012-12-31 | CN¥1.14 Billion ≈ $166.24 Million |
+12.08% |
| 2011-12-31 | CN¥1.01 Billion ≈ $148.33 Million |
-- |
About Sunflower Pharmaceuticals Group Co Ltd
Sunflower Pharmaceutical Group Co.,Ltd engages in the research and development, manufacturing, and marketing of Chinese patent medicines in China and internationally. The company produces chemical and biological medicines, and health care products. It also provides products covering various therapeutic areas, including pediatrics, gynecology, adult digestive system, respiratory and cold, rheumati… Read more